640 related articles for article (PubMed ID: 28366767)
1. FDA-Approved Oligonucleotide Therapies in 2017.
Stein CA; Castanotto D
Mol Ther; 2017 May; 25(5):1069-1075. PubMed ID: 28366767
[TBL] [Abstract][Full Text] [Related]
2. Designing Effective Antisense Oligonucleotides for Exon Skipping.
Shimo T; Maruyama R; Yokota T
Methods Mol Biol; 2018; 1687():143-155. PubMed ID: 29067661
[TBL] [Abstract][Full Text] [Related]
3. The 10th Oligonucleotide Therapy Approved: Golodirsen for Duchenne Muscular Dystrophy.
Aartsma-Rus A; Corey DR
Nucleic Acid Ther; 2020 Apr; 30(2):67-70. PubMed ID: 32043902
[No Abstract] [Full Text] [Related]
4. [Oligonucleotide therapeutics - an emerging novel class of compounds].
Wacheck V
Wien Med Wochenschr; 2006 Sep; 156(17-18):481-7. PubMed ID: 17041803
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotide drugs for Duchenne muscular dystrophy: how far have we come and what does the future hold?
Guncay A; Yokota T
Future Med Chem; 2015; 7(13):1631-5. PubMed ID: 26423833
[No Abstract] [Full Text] [Related]
6. FDA Approval of Nusinersen for Spinal Muscular Atrophy Makes 2016 the Year of Splice Modulating Oligonucleotides.
Aartsma-Rus A
Nucleic Acid Ther; 2017 Apr; 27(2):67-69. PubMed ID: 28346110
[No Abstract] [Full Text] [Related]
7. Treating Disease at the RNA Level with Oligonucleotides.
Levin AA
N Engl J Med; 2019 Jan; 380(1):57-70. PubMed ID: 30601736
[No Abstract] [Full Text] [Related]
8. Eteplirsen: First Global Approval.
Syed YY
Drugs; 2016 Nov; 76(17):1699-1704. PubMed ID: 27807823
[TBL] [Abstract][Full Text] [Related]
9. Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease.
Sardone V; Zhou H; Muntoni F; Ferlini A; Falzarano MS
Molecules; 2017 Apr; 22(4):. PubMed ID: 28379182
[TBL] [Abstract][Full Text] [Related]
10. FDA Approves Eteplirsen for Duchenne Muscular Dystrophy: The Next Chapter in the Eteplirsen Saga.
Aartsma-Rus A; Krieg AM
Nucleic Acid Ther; 2017 Feb; 27(1):1-3. PubMed ID: 27929755
[No Abstract] [Full Text] [Related]
11. Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision.
Orr RM
Curr Opin Mol Ther; 2001 Jun; 3(3):288-94. PubMed ID: 11497353
[TBL] [Abstract][Full Text] [Related]
12. Antisense Oligonucleotides: A Unique Treatment Approach.
Krishnan AV; Mishra D
Indian Pediatr; 2020 Feb; 57(2):165-171. PubMed ID: 32060244
[TBL] [Abstract][Full Text] [Related]
13. Genetic therapies for inherited neuromuscular disorders.
Scoto M; Finkel R; Mercuri E; Muntoni F
Lancet Child Adolesc Health; 2018 Aug; 2(8):600-609. PubMed ID: 30119719
[TBL] [Abstract][Full Text] [Related]
14. Development of Antisense Oligonucleotide Gapmers for the Treatment of Dyslipidemia and Lipodystrophy.
Aslesh T; Yokota T
Methods Mol Biol; 2020; 2176():69-85. PubMed ID: 32865783
[TBL] [Abstract][Full Text] [Related]
15. Nusinersen: antisense oligonucleotide to increase SMN protein production in spinal muscular atrophy.
Paton DM
Drugs Today (Barc); 2017 Jun; 53(6):327-337. PubMed ID: 28799578
[TBL] [Abstract][Full Text] [Related]
16. Eteplirsen Approved for Duchenne Muscular Dystrophy: The FDA Faces a Difficult Choice.
Stein CA
Mol Ther; 2016 Nov; 24(11):1884-1885. PubMed ID: 27916994
[No Abstract] [Full Text] [Related]
17. Chemistry, structure and function of approved oligonucleotide therapeutics.
Egli M; Manoharan M
Nucleic Acids Res; 2023 Apr; 51(6):2529-2573. PubMed ID: 36881759
[TBL] [Abstract][Full Text] [Related]
18. Exon Skipping Therapy Using Phosphorodiamidate Morpholino Oligomers in the mdx52 Mouse Model of Duchenne Muscular Dystrophy.
Miyatake S; Mizobe Y; Takizawa H; Hara Y; Yokota T; Takeda S; Aoki Y
Methods Mol Biol; 2018; 1687():123-141. PubMed ID: 29067660
[TBL] [Abstract][Full Text] [Related]
19. Advances in therapy for spinal muscular atrophy: promises and challenges.
Groen EJN; Talbot K; Gillingwater TH
Nat Rev Neurol; 2018 Apr; 14(4):214-224. PubMed ID: 29422644
[TBL] [Abstract][Full Text] [Related]
20. [Gene-specific treatment approaches in muscle diseases].
Lehmann Urban D; Schneider I
Nervenarzt; 2020 Apr; 91(4):318-323. PubMed ID: 32076754
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
